Literature DB >> 2795722

Antiviral effect of lymphokine-activated killer cells: chemotaxis and homing to sites of virus infection.

R J Natuk1, J F Bukowski, J O Brubaker, R M Welsh.   

Abstract

Lymphokine-activated killer (LAK) cells generated from C57BL/6 mouse spleen cells cultured with interleukin-2 are effective prophylactically against virus infection when inoculated at the site of virus injection. To predict the therapeutic efficacy of LAK cells, we determined whether LAK cells would home to sites of virus infection. In vitro, LAK cells responded chemotactically to cell-free peritoneal exudate fluids collected from virus-infected mice and to preparations of purified beta interferon. In vivo, radiolabeled LAK cells injected intravenously accumulated in the peritoneal cavities of intraperitoneally infected mice in amounts three to eight times greater than in uninfected mice. This ability to respond to chemotactic agents and migrate into sites of virus infection may make LAK cells useful as antiviral therapeutic agents.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2795722      PMCID: PMC251148     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  18 in total

1.  Nonspecific entry of thoracic duct immunoblasts into intradermal foci of antigens.

Authors:  A R Moore; J G Hall
Journal:  Cell Immunol       Date:  1973-07       Impact factor: 4.868

2.  In vivo natural reactivity of mice against tumor cells.

Authors:  C Riccardi; A Santoni; T Barlozzari; P Puccetti; R B Herberman
Journal:  Int J Cancer       Date:  1980-04-15       Impact factor: 7.396

3.  Site-specific mutagenesis of the human interleukin-2 gene: structure-function analysis of the cysteine residues.

Authors:  A Wang; S D Lu; D F Mark
Journal:  Science       Date:  1984-06-29       Impact factor: 47.728

4.  Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.

Authors:  S A Rosenberg; M T Lotze; L M Muul; S Leitman; A E Chang; S E Ettinghausen; Y L Matory; J M Skibber; E Shiloni; J T Vetto
Journal:  N Engl J Med       Date:  1985-12-05       Impact factor: 91.245

5.  Biological activity of recombinant human interleukin-2 produced in Escherichia coli.

Authors:  S A Rosenberg; E A Grimm; M McGrogan; M Doyle; E Kawasaki; K Koths; D F Mark
Journal:  Science       Date:  1984-03-30       Impact factor: 47.728

6.  Antiviral effect of lymphokine-activated killer cells: characterization of effector cells mediating prophylaxis.

Authors:  J F Bukowski; H Yang; R M Welsh
Journal:  J Virol       Date:  1988-10       Impact factor: 5.103

7.  The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo.

Authors:  J J Mulé; S Shu; S A Rosenberg
Journal:  J Immunol       Date:  1985-07       Impact factor: 5.422

8.  Murine lymphokine-activated killer (LAK) cells: phenotypic characterization of the precursor and effector cells.

Authors:  J C Yang; J J Mulé; S A Rosenberg
Journal:  J Immunol       Date:  1986-07-15       Impact factor: 5.422

9.  Adoptive transfer studies demonstrating the antiviral effect of natural killer cells in vivo.

Authors:  J F Bukowski; J F Warner; G Dennert; R M Welsh
Journal:  J Exp Med       Date:  1985-01-01       Impact factor: 14.307

10.  Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.

Authors:  E A Grimm; A Mazumder; H Z Zhang; S A Rosenberg
Journal:  J Exp Med       Date:  1982-06-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.